Xenical vs Mounjaro: two very different approaches to weight loss

The biggest misconception: that orlistat and tirzepatide are in the same league

A lot of readers arrive at this comparison assuming Xenical and Mounjaro are roughly equivalent options, perhaps at different price points. They are not. Orlistat, the active ingredient in Xenical, has been available in the UK for over two decades and works by blocking an enzyme in the gut called lipase. Block lipase, and roughly a third of the fat you eat passes through unabsorbed rather than entering your bloodstream. It does not touch your appetite, your hunger hormones, or the way your brain processes fullness. In practice, this means the medicine is only effective when dietary fat is genuinely restricted, and produces well-documented gastrointestinal side effects (loose stools, oily leakage, urgency) when fat intake is not reduced.

Mounjaro is a dual GIP and GLP-1 receptor agonist. It mimics two gut hormones that regulate appetite and blood sugar, slows the rate at which your stomach empties, and reduces how hungry you feel between meals. The mechanism operates upstream of the plate, not downstream of it. In SURMOUNT-1, the pivotal 72-week trial, participants on the 15 mg dose lost around 20–21% of their body weight on average, a figure that sits well ahead of anything orlistat trials have produced. The NHS tirzepatide page sets out the mechanism and common side effects in plain terms.

The myth, then, is that this is a close call. The clinical evidence suggests it is not, though that does not automatically make Mounjaro the right choice for every individual.

What Xenical's licence and results actually look like alongside Mounjaro's

The table below compares the two medicines on the dimensions most readers want to know about. Numbers are taken from published trial data and current UK licensing; prescribers will have a more detailed picture of your individual situation.

Orlistat's results, while modest, are real and it has a long safety record. For a patient who cannot tolerate injections, or who has a contraindication to GLP-1 based medicines, it remains a licensed option. Our treatment overview page covers the range of options available through a private prescription.

Who each medicine is licensed for, and why that matters here

Both medicines require a clinical assessment and a prescription. Neither is available legally without one, and this is worth emphasising: sellers offering prescription weight-loss medicines without a consultation are operating outside UK law.

Xenical 120 mg is prescription-only (a lower-strength 60 mg version, Alli, is available over the counter). Its licence covers adults with a BMI of 30 or above, or 28 and above with a weight-related risk factor such as high blood pressure or type 2 diabetes. Treatment should be stopped if less than 5% of body weight is lost after 12 weeks on the full dose.

Mounjaro's UK licence covers adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, a slightly lower starting threshold for those with comorbidities. NICE recommends it for NHS use in adults with a BMI of 35 or above and at least one qualifying condition, with lower thresholds applying for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Through a regulated private pharmacy like nume, the licensed eligibility criteria apply rather than the narrower NHS criteria. Treatment starts at a 2.5 mg starter dose to allow your system to adjust, then is titrated by the prescriber over several months.

If you are comparing the two because Mounjaro has a waiting list in your area or your GP has not offered it yet, it is worth reading how private access to Mounjaro works in practice. Timing can matter more than people expect: a patient who begins a consultation mid-month, say around payday when many people book, can still receive their first pen the next working day once clinically approved.

How a clinical decision is actually made between these two

A prescriber weighing Xenical against Mounjaro for a specific patient is thinking about several things at once: the degree of weight loss likely needed for health benefit, any contraindications to GLP-1 medicines (a history of pancreatitis or medullary thyroid carcinoma, for example), whether the patient can manage a weekly injection, and what the patient themselves wants. Cost and NHS availability may also be practical factors.

For most eligible adults, the published evidence favours tirzepatide by a considerable margin on weight outcomes. If you want to understand how tirzepatide fits among the wider class of injectable treatments, our guide comparing GLP-1 medicines with Mounjaro gives more context on where tirzepatide sits among the newer injectable options. Those curious about how Mounjaro compares with emerging alternatives can also explore the retatrutide comparison, though that medicine is not yet licensed in the UK.

Our prescribers at the nume clinical team review every consultation personally. There is no algorithm deciding your suitability. If Mounjaro is appropriate for you, we will say so clearly; if it is not, we will say that too. For anyone who finds it helpful to see photos showing the Mounjaro pen and injection process, we have put together a visual guide to what treatment looks like in practice. If you have been using Saxenda and are wondering whether switching makes sense, our Saxenda versus Mounjaro comparison sets out the key clinical differences. Readers who are still unclear on how tirzepatide and Mounjaro relate to each other will find that question answered directly before moving on to the FAQs. Common questions about the consultation process are answered on our FAQs page. Which medicine suits you is ultimately a clinical decision made together with your prescriber, not one a comparison table can make for you.